Table 2.
Tetramer staining of patient CD8+ T cells presensitized with NY-ESO-1 peptides
|
In vitro stimulation of T cells with:
|
||||
|---|---|---|---|---|
| S9C | S11L | L9L | Adeno/ESO | |
| Patient NW1288: Preexisting immunity to NY-ESO-1—Not vaccinated | ||||
| S9C-tetramer | 1.48% | 1.58% | 0.04% | 1.01% |
| S11L-tetramer | 0.10% | 0.10% | 0.02% | 0.02% |
| L9L-tetramer | 0.03% | 0.17% | 0.04% | 0.03% |
| Patient NW886: No preexisting immunity to NY-ESO-1—Vaccinated with S9C and S11L | ||||
| S9C-tetramer | 0.04% | 0.06% | ND | 0.13% |
| S11L-tetramer | 0.02% | 0.03% | ND | 0.06% |
| L9L-tetramer | 0.05% | 3.98% | ND | 0.06% |
| Patient NW924: Preexisting immunity to NY-ESO-1—Vaccinated with S9C and S11L | ||||
| S9C-tetramer | 9.72% | 5.88% | ND | 0.43% |
| S11L-tetramer | 0.09% | 0.13% | ND | 0.02% |
| L9L-tetramer | 0.16% | 5.59% | ND | 0.06% |
CD8+ T lymphocytes were presensitized in vitro with S9C, S11L, L9L, or adenovirus recombinant for NY-ESO-1 (Adeno/ESO) and assayed on day 8 (patient NW1288), day 26 (patient NW886), or day 11 (patient NW924). ND, not determined. Bold numbers represent detectable tetramer-positive populations.